Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Avalyn Pharma Inc. shares jumped 44% in its trading debut, after the biopharmaceutical company raised $300 million in an upsized US initial public offering.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.